INCOME TAXES	6 Months Ended
Jun. 30, 2013
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES During the three and six months ended June 30, 2013, the Company recorded a provision for income taxes of approximately $0.5 million and $1.2 million, respectively. The provision for income taxes primarily consisted of foreign taxes. Due to the Company’s history of cumulative operating losses, management concluded that, after considering all the available objective evidence, it is not more likely than not that all the Company’s net deferred tax assets will be realized. Accordingly, all of the U.S. deferred tax assets continue to be subject to a valuation allowance as of June 30, 2013. As of June 30, 2013, there have been no material changes to the total amount of unrecognized tax benefits. During the three and six months ended June 30, 2012, the company recorded an income tax benefit of approximately $37.0 million and $37.1 million, respectively. The income tax benefit resulted primarily from a reduction in the valuation allowance recorded against the Company's net deferred tax assets of $37.5 million recorded during the second quarter of 2012, due to deferred tax liabilities recognized for the difference between the fair value and carrying basis of certain tangible and intangible assets obtained as part of the Acquisition, which can be used as a source of income to support realization of certain domestic deferred tax assets. As described in the Company's Quarterly Report on Form 10-Q for the nine months ended September 30, 2012 in Note 2. "Acquisition", the Condensed Consolidated Statements of Operations for the six months ended June 30, 2012 includes adjustments that were made upon finalization of the valuation of certain assets acquired and liabilities assumed from the acquisition of eBioscience Holdings, Inc. ("eBioscience"). Deferred tax liabilities recognized for the difference between the fair value and carrying basis of certain tangible and intangible assets obtained as part of the Acquisition can be used as a source of income when utilizing certain domestic deferred tax assets. The aforementioned purchase accounting adjustments that reduced certain tangible and intangible assets and reduced the related deferred tax liabilities resulted in an increase in the valuation allowance recorded against the Company's consolidated net deferred tax assets. Under Accounting Standards Codification ("ASC") 805-740, changes in an acquirer's valuation allowances that stem from a business combination should be recognized as an element of the acquirer's deferred income tax expense (benefit) in the reporting period that includes the business combination. Such purchase accounting adjustments (also referred to as “measurement period adjustments”) are considered to have occurred as of June 25, 2012 (the "Acquisition Date"). As a result of the retrospective purchase accounting and related income tax valuation adjustments from the Acquisition, the Company recast its income tax benefit for the second quarter of 2012, lowering it by $7.2 million from net $44.3 million with a corresponding increase in valuation allowance. The Company's Condensed Consolidated Financial Statements as of and for the period ended June 30, 2012, were recast to reflect these adjustments.

INCOME TAXES

6 Months Ended

Jun. 30, 2013

During the three and six months ended June 30, 2013, the Company recorded a provision for income taxes of approximately $0.5 million and $1.2 million, respectively. The provision for income taxes primarily consisted of foreign taxes.

Due to the Company’s history of cumulative operating losses, management concluded that, after considering all the available objective evidence, it is not more likely than not that all the Company’s net deferred tax assets will be realized. Accordingly, all of the U.S. deferred tax assets continue to be subject to a valuation allowance as of June 30, 2013.

As of June 30, 2013, there have been no material changes to the total amount of unrecognized tax benefits.

During the three and six months ended June 30, 2012, the company recorded an income tax benefit of approximately $37.0 million and $37.1 million, respectively. The income tax benefit resulted primarily from a reduction in the valuation allowance recorded against the Company's net deferred tax assets of $37.5 million recorded during the second quarter of 2012, due to deferred tax liabilities recognized for the difference between the fair value and carrying basis of certain tangible and intangible assets obtained as part of the Acquisition, which can be used as a source of income to support realization of certain domestic deferred tax assets.

As described in the Company's Quarterly Report on Form 10-Q for the nine months ended September 30, 2012 in Note 2. "Acquisition", the Condensed Consolidated Statements of Operations for the six months ended June 30, 2012 includes adjustments that were made upon finalization of the valuation of certain assets acquired and liabilities assumed from the acquisition of eBioscience Holdings, Inc. ("eBioscience"). Deferred tax liabilities recognized for the difference between the fair value and carrying basis of certain tangible and intangible assets obtained as part of the Acquisition can be used as a source of income when utilizing certain domestic deferred tax assets. The aforementioned purchase accounting adjustments that reduced certain tangible and intangible assets and reduced the related deferred tax liabilities resulted in an increase in the valuation allowance recorded against the Company's consolidated net deferred tax assets. Under Accounting Standards Codification ("ASC") 805-740, changes in an acquirer's valuation allowances that stem from a business combination should be recognized as an element of the acquirer's deferred income tax expense (benefit) in the reporting period that includes the business combination. Such purchase accounting adjustments (also referred to as “measurement period adjustments”) are considered to have occurred as of June 25, 2012 (the "Acquisition Date"). As a result of the retrospective purchase accounting and related income tax valuation adjustments from the Acquisition, the Company recast its income tax benefit for the second quarter of 2012, lowering it by $7.2 million from net $44.3 million with a corresponding increase in valuation allowance. The Company's Condensed Consolidated Financial Statements as of and for the period ended June 30, 2012, were recast to reflect these adjustments.